Sub‐lineages of the SARS‐CoV‐2 Omicron variants: Characteristics and prevention

Ailan Xu, Bixia Hong, Fuxing Lou, Shuqi Wang, Wenye Li, Amna Shafqat, Xiaoping An, Yunwei Zhao, Lihua Song, Yigang Tong, Huahao FanMedComm 2022 · DOI

TL;DR

This review comprehensively details the Omicron variant of SARS-CoV-2, its numerous sub-lineages (like BA.1, BA.2, BA.4, BA.5), and their enhanced transmissibility and immune evasion capabilities. It highlights the urgent need for updated vaccines and effective preventive strategies to combat the ongoing threat of Omicron and its future iterations.

What Problem Does This Paper Address?

The COVID-19 pandemic has been characterized by the continuous emergence of new SARS-CoV-2 variants, each posing unique challenges. The Omicron variant, identified in late 2021, quickly became the dominant strain due to its rapid spread and significant immune escape properties, largely attributed to its extensive mutations. This presented a critical problem: how to understand and effectively counter this new wave of the virus, which threatened to undermine existing vaccines and treatments. This paper addresses this by providing a detailed overview of Omicron's characteristics, its sub-lineages, and the implications for prevention and treatment, aiming to guide public health responses.

Methods

This paper is a review article, meaning it synthesizes existing research rather than presenting new experimental data. The authors have meticulously reviewed and compiled findings from numerous studies, including:

  • Epidemiological data analysis: Examining case numbers, spread patterns, and hospitalization rates across different regions and timeframes.
  • Molecular and genetic analysis: Investigating the specific mutations within the Omicron variant and its sub-lineages, particularly in the spike protein, and their correlation with altered biological properties.
  • Immunological studies: Analyzing data from in vitro neutralization experiments using sera from vaccinated individuals, convalescent patients, and those who received booster shots to assess immune escape.
  • Clinical observations: Summarizing findings on disease severity, symptoms, and treatment outcomes associated with Omicron infections.
  • Computational modeling and prediction: Utilizing models to understand transmission dynamics and predict evolutionary trends.

Datasets

Not discussed in the paper. As a review article, it synthesizes data from numerous published studies, rather than collecting or analyzing a specific dataset.

Key Insights and Ideas

  • Omicron's Mutation Powerhouse: Omicron's defining characteristic is its sheer number of mutations, far exceeding previous variants like Alpha, Beta, Gamma, and Delta. This genetic plasticity is the root cause of its enhanced transmissibility and immune evasion.
  • Sub-lineage Proliferation: The rapid emergence of multiple Omicron sub-lineages (BA.1, BA.2, BA.4, BA.5, etc.) highlights the virus's ongoing evolution and its ability to adapt and outcompete previous strains.
  • Immune Evasion is Real: Existing vaccines and even prior infection with other variants offer significantly reduced protection against Omicron, necessitating booster shots and the development of variant-specific vaccines.
  • "Natural Vaccine" Myth Debunked: The idea that infection with Omicron itself acts as a natural vaccine is unrealistic, as it often fails to elicit sufficient neutralizing antibodies against Omicron itself.
  • Drug Sensitivity Varies: While some antiviral drugs remain effective, others show reduced efficacy against Omicron, underscoring the need for ongoing drug development and monitoring.
  • Cellular Immunity Holds Stronger: While antibody responses are significantly impacted, T-cell immunity appears to remain largely effective against Omicron, offering some level of protection.

Key Results

  • Increased Transmissibility: Omicron variants demonstrate significantly higher transmissibility compared to previous variants, with some estimates suggesting a 100.3% higher infection capacity than the wild-type.
  • Reduced Vaccine Efficacy: Neutralizing antibody titers against Omicron are substantially reduced (often by 15-30 fold or more) in individuals vaccinated with two doses of mRNA vaccines, compared to the wild-type strain. Booster doses significantly improve this, but protection still wanes.
  • Monoclonal Antibody Resistance: Many previously effective monoclonal antibodies have lost their neutralizing activity against Omicron due to mutations in key regions like the RBD.
  • Milder Disease (Often): While Omicron's immune evasion is high, clinical data often suggests a milder disease presentation compared to Delta, particularly in vaccinated individuals. However, high infection rates can still overwhelm healthcare systems.
  • Wastewater Surveillance Success: Omicron variants have been successfully detected in wastewater, demonstrating its utility as an early warning system for variant spread.

Limitations and Future Work

  • Evolving Landscape: The rapid emergence of new sub-lineages means that findings can quickly become outdated. Continuous monitoring and research are crucial.
  • Long-term Efficacy: While boosters enhance protection, the long-term durability of this protection against Omicron and future variants remains an area requiring further study.
  • Universal Vaccines: The authors emphasize the need for developing universal vaccines that can provide broad protection against a wide range of SARS-CoV-2 variants, rather than constantly updating vaccines for each new strain.
  • Therapeutic Development: Further research is needed to identify and validate effective antiviral drugs and therapeutic strategies specifically for Omicron and its future iterations.
  • Understanding Disease Severity: While generally milder, the factors contributing to severe Omicron disease in certain individuals and populations require deeper investigation.

Summary updated

Abstract

Since the start of the coronavirus disease 2019 (COVID-19) pandemic, new variants of severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) have emerged, accelerating the spread of the virus. Omicron was defined by the World Health Organization in November 2021 as the fifth "variant of concern" after Alpha, Beta, Gamma, and Delta. In recent months, Omicron has become the main epidemic strain. Studies have shown that Omicron carries more mutations than Alpha, Beta, Gamma, Delta, and wild-type, facilitating immune escape and accelerating its transmission. This review focuses on the Omicron variant's origin, transmission, main biological features, subvariants, mutations, immune escape, vaccination, and detection methods. We also discuss the appropriate preventive and therapeutic measures that should be taken to address the new challenges posed by the Omicron variant. This review is valuable to guide the surveillance, prevention, and development of vaccines and other therapies for Omicron variants. It is desirable to develop a more efficient vaccine against the Omicron variant and take more effective measures to constrain the spread of the epidemic and promote public health.
BibTeX
@inproceedings{xu2022sublineages,
  author = {Ailan Xu and Bixia Hong and Fuxing Lou and Shuqi Wang and Wenye Li and Amna Shafqat and Xiaoping An and Yunwei Zhao and Lihua Song and Yigang Tong and Huahao Fan},
  title = {{Sub‐lineages of the SARS‐CoV‐2 Omicron variants: Characteristics and prevention}},
  booktitle = {MedComm},
  year = {2022},
  doi = {10.1002/mco2.172},
}
Figure